This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: F. Hoffmann-La Roche Ag. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Michael Wenger - Innovator in Cancer Treatment
Introduction
Michael Wenger is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of oncology, particularly in the treatment of CD20-positive B-cell lymphoma. His innovative approach focuses on the administration speed of obinutuzumab, a monoclonal antibody used in cancer therapy.
Latest Patents
Michael Wenger holds 1 patent related to his work. The patent specifically addresses the treatment of CD20-positive B-cell lymphoma with obinutuzumab. This advancement aims to enhance the efficacy of the treatment by optimizing the administration process.
Career Highlights
Wenger is currently employed at F. Hoffmann-La Roche AG, a leading global healthcare company. His role involves research and development in cancer therapies, where he applies his expertise to improve patient outcomes. His work has been instrumental in advancing treatment options for patients suffering from B-cell lymphoma.
Collaborations
Michael Wenger collaborates with Mehrdad Mobasher, a fellow researcher in the field. Together, they work on innovative solutions to enhance cancer treatment methodologies.
Conclusion
Michael Wenger's contributions to cancer treatment through his patent on obinutuzumab administration speed exemplify his commitment to improving patient care. His work at F. Hoffmann-La Roche AG continues to influence the landscape of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile